Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe United States | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | es
Brazil | pt
Canada | en
Canada | fr
Central America | es
Colombia | es
Latin America | es
Mexico | es
United States | en
Venezuela | es
Australia | en
Bangladesh | en
Hong Kong S.A.R. | zh
India | en
Indonesia | en
Japan | ja
Korea | ko
Mainland China | zh
Malaysia | en
Pakistan | en
Philippines | en
Taiwan | zh
Austria | de
Belgium | fr
Belgium | nl
Bulgaria | bg
Czech Republic | cs
Czech Republic | en
Denmark | da
Estonia | et
Finland | fi
France | fr
Germany | de
Greece | el
Hungary | hu
Ireland | en
Italy | it
Latvia | lv
Lithuania | lt
Netherlands | nl
Norway | no
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Serbia | sr
Singapore | en
Slovakia | sk
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
United Kingdom | en
Global | en
Novartis Foundation | en
Sandoz | en
Egypt | en
South Africa | en
Turkey | tr

Language & Country Selector for Mobile

language-selector-globe US

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
Argentina | es
Australia | en
Austria | de
Bangladesh | en
Belgium | fr
Belgium | nl
Brazil | pt
Bulgaria | bg
Canada | en
Canada | fr
Central America | es
Colombia | es
Czech Republic | cs
Czech Republic | en
Denmark | da
Egypt | en
Estonia | et
Finland | fi
France | fr
Germany | de
Global | en
Greece | el
Hong Kong S.A.R. | zh
Hungary | hu
India | en
Indonesia | en
Ireland | en
Italy | it
Japan | ja
Korea | ko
Latin America | es
Latvia | lv
Lithuania | lt
Mainland China | zh
Malaysia | en
Mexico | es
Netherlands | nl
Norway | no
Novartis Foundation | en
Pakistan | en
Philippines | en
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Sandoz | en
Serbia | sr
Singapore | en
Slovakia | sk
South Africa | en
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
Taiwan | zh
Turkey | tr
United Kingdom | en
United States | en
Venezuela | es
    • About 
      • Novartis in the US 
        • Company at a Glance 
        • By the Numbers 
        • Diversity and Inclusion 
        • Pay Transparency-EPIC 
        • Our Code of Ethics 
      • Strategy 
      • Diversity and Inclusion 
        • Ensuring Equity 
        • The Spirit of Inclusivity 
        • Toward a better society 
        • Parental Leave 
        • Standing for Racial Equity and Justice as One Novartis 
        • Novartis US EEO / D&I Report 2021 
        • Supplier Diversity 
      • People and Culture 
      • Products 
      • Country Leadership Team 
      • External Funding 
      • Contact Us 
      Woman scientist in lab About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Patient Assistance 
      • Diseases 
      • Participating in Clinical Trials 
      • Patient Perspectives 
      • Adverse Event Reporting 
      • The STEP Program 
        • Sickle Cell Disease (SCD) 
        • Program Overview 
        • Multiple Sclerosis (MS) 
        • Cancer 
        • Application for Funding to Help Address Health Disparities 
        • Health Disparities 
      Patient smiling at doctor image Patients and Caregivers
    • Healthcare Professionals 
      • Novartis Pipeline 
      • Novartis Clinical Trials 
      • Adverse Event Reporting 
      Two doctors examining X-ray Healthcare Professionals
    • ESG 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
        • PhRMA Code on Interactions with Healthcare Professionals 
        • Business Principles 
      • Ethics, Risk and Compliance 
        • Compliance Program 
        • State Laws 
        • Corporate Integrity Agreement 
        • Payments to HCPs & HCOs 
        • Enhanced Verification Request 
      • Corporate Responsibility 
        • Population Health 
        • Novartis in Society US Reports 
        • Novartis US Foundation 
        • Environmental Sustainability 
        • People and Communities 
      • Beacon of Hope 
        • Beacon of Hope: Measurable solutions for health equity 
      Novartis East Hanover Campus Landscaping ESG
    • News 
      • News Archive 
      • Statements 
      • Stories 
      • Contacts 
      Co-workers having a meeting News
    • Careers 
      • Career Search 
      • Meet the Teams 
      • Early Career 
      • Personal Growth 
      • How We Work 
      • Employee Benefits 
      • Diversity and Inclusion 
      • Awards & Recognition 
      Meeting in Atrium Careers
    Novartis East Hanover Campus East Village Promenade Home
Placeholder Image

Innovation

Tags Archive Navigation
  • All
  • Careers
  • Feature News
  • In the News
  • Media Releases
  • Story
icon
  • Media Release
    Jun 08, 2023
    Novartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease
  • Media Release
    Jun 07, 2022
    Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
  • Media Release
    Nov 22, 2022
    Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
  • Media Release
    Jun 22, 2022
    Novartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparities
  • Media Release
    Dec 13, 2022
    Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
  • Media Release
    Dec 08, 2022
    Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
  • Media Release
    Dec 06, 2022
    Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
  • Media Release
    Apr 20, 2023
    Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
  • Media Release
    Mar 27, 2023
    Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
  • Media Release
    Jun 02, 2023
    Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
  • Media Release
    May 27, 2022
    FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
  • Media Release
    Apr 06, 2022
    FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Pagination

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 47
  • › Next page

Novartis United States

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Statements
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Other Novartis US Websites
  • Oncology HCP Resources
  • Gene Therapy Network
  • Medical Information
  • Sandoz
  • Global Site
Footer Bottom
© 2023 Novartis Pharmaceuticals Corporation
  • Terms of Use
  • Privacy Policy
  • Contacts
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for US Residents Only